Olympus Launches SecureFlex Biopsy Device for Pancreatic Cancer Diagnosis
Olympus Corporation has launched the SecureFlex Single-use Fine Needle Biopsy Device in Europe, the Middle East, and Africa (EMEA). The device, set to hit the market in autumn 2025, is primarily used in the diagnosis of pancreatic cancer.
SecureFlex, designed for use with an ultrasound endoscope, is ideal for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) of gastrointestinal tract lesions. Its innovative Dual-Beveled Raptor Tip ensures larger, more intact tissue samples, boosting diagnostic accuracy. The device's flexible nitinol construction and multi-layer sheath design allow smooth navigation to complex anatomical structures. It will be commercially available in Europe and Japan this autumn, with a global rollout planned for later, subject to regulatory requirements.
The SecureFlex device, launched by Olympus Corporation, promises enhanced diagnostic capabilities in pancreatic cancer diagnosis. Its innovative features and smooth navigation design are expected to improve patient care and outcomes. The device will be available in Europe and Japan this autumn, with a wider global rollout to follow.
Read also:
- New Immigration Law Guide: Practical Advice for Legal Professionals
- Willich's Senior Citizens Prepare for Council Elections, City Celebrates International Day of Older Persons
- Chronic Stress: Holistic Management for Physical and Mental Health
- St. John's Hospital in Pay Dispute Over CEO's Salary Increase
